Home » Stocks » STML

Stemline Therapeutics, Inc. (STML)

Jun 10, 2020 - STML was delisted (reason: company went private)
Stock Price: $11.83 USD 0.00 (0.00%)
Updated Jun 10, 2020 4:00 PM EDT
Market Cap 621.20M
Revenue (ttm) 47.04M
Net Income (ttm) -70.70M
Shares Out 52.50M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE 17.92
Dividend n/a
Dividend Yield n/a
Trading Day Jun 10, 2020
Last Price $11.83
Previous Close $11.83
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 11.82 - 12.10
Day's Volume 0
52-Week Range 3.21 - 18.22

News

Hide News
Zacks Investment Research - 8 months ago

Stemline Therapeutics (STML) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Motley Fool - 8 months ago

Here's what's behind their impressive market performances.

Other stocks mentioned: MGNX, PTGX
The Motley Fool - 8 months ago

The ultimate binary event caused the biotech's shares to jump.

Benzinga - 8 months ago

The New York-based oncology-focused, commercial-stage biopharma Stemline Therapeutics Inc (NASDAQ: STML) ringed in merger Monday with a go-private deal valued at up to $667 million.

Market Watch - 8 months ago

Privately held Menarini Group, an Italian drug and diagnostics company, said Monday it has agreed to acquire Stemline Therapeutics Inc.

GlobeNewsWire - 8 months ago

FLORENCE, Italy and NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-s...

Zacks Investment Research - 8 months ago

Stemline Therapeutics (STML) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GuruFocus - 9 months ago

Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost mo...

Other stocks mentioned: KALV
GuruFocus - 9 months ago

Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost mo...

Other stocks mentioned: KALV
Seeking Alpha - 10 months ago

Stemline Therapeutics, Inc. (STML) CEO Ivan Bergstein on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Stemline Therapeutics (STML) delivered earnings and revenue surprises of 2.56% and 0.08%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...

Seeking Alpha - 11 months ago

Stemline Therapeutics: Down, But Not Out

The Motley Fool - 1 year ago

The launch of blood cancer drug Elzonris is slowing.

Seeking Alpha - 1 year ago

2 Small Biotech Stocks To Buy For 2020

Other stocks mentioned: KPTI
Seeking Alpha - 1 year ago

Shares have lost a third of their value since my August recommendation.

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

Seeking Alpha - 1 year ago

Stemline Therapeutics, Inc. (STML) CEO Ivan Bergstein on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of nove...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of nove...

Seeking Alpha - 1 year ago

The stock of Stemline Therapeutics has fallen approximately 30% from recent highs over the past month.

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of nove...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of nove...

GuruFocus - 1 year ago

CEO of Stemline Therapeutics Inc (30-Year Financial, Insider Trades) Ivan Bergstein (insider trades) sold 35,010 shares of STML on 08/14/2019 at an average price of $14.73 a share.

Seeking Alpha - 1 year ago

Stemline Therapeutics, Inc. (STML) CEO Ivan Bergstein on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Stemline Therapeutics (STML) delivered earnings and revenue surprises of 10.64% and 47.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the ...

Seeking Alpha - 1 year ago

Today, we revisit Stemline Therapeutics, a developmental concern advancing its pipeline and rolling out its first approved product.

Benzinga - 1 year ago

Stemline Therapeutics Inc. reported a wider first-quarter net loss per share Friday, dragged by higher R&D expenses, which nearly tripled from a year ago.

Seeking Alpha - 1 year ago

Stemline Therapeutics' (STML) CEO Ivan Bergstein on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Stemline Therapeutics (STML) delivered earnings and revenue surprises of -8.96% and 93.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the...

Seeking Alpha - 1 year ago

Today we revisit Stemline Therapeutics, a member of the 20-stock Busted IPO Forum model portfolio.

About STML

Stemline Therapeutics, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis... [Read more...]

Industry
Biotechnology
IPO Date
Jan 29, 2013
CEO
Ivan Bergstein
Employees
100
Stock Exchange
NASDAQ
Ticker Symbol
STML
Full Company Profile

Financial Performance

In 2019, STML's revenue was $43.22 million, an increase of 8,543.37% compared to the previous year's $500,000. Losses were -$76.82 million, -9.65% less than in 2018.

Financial Statements